FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943360147> ?p ?o ?g. }

• W2943360147 abstract "Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017–000105-20; ClinicalTrials.gov Identifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival. The study is designed as an open-label, single arm, prospective, monocenter, phase II study including 30 patients with NSCLC stage II/IIIA suitable for curative intent surgery. Investigational drug is Pembrolizumab. After 2 cycles of immunotherapy (à 200 mg q3w i.v.), tumor resection with lobectomy or bilobectomy will be performed. Primary objectives are to assess the feasibility and safety of a neoadjuvant immunotherapy and to assess antitumor activity of Pembrolizumab with regard to clinical and pathological tumor response. Secondary objective is disease free and overall survival. Exploratory objective is to analyze potential predictive biomarkers and to evaluate the therapeutic efficacy of Pembrolizumab by extended immune cell and cytokine analysis of tumor tissue. The study protocol was approved by the local ethics committee and the federal authority. Start of patient enrollment is scheduled for June 2018. The NEOMUN trial will be one of the first clinical trials investigating a multimodal treatment strategy including neoadjuvant immunotherapy using Pembrolizumab as an investigational drug. Assessing the safety and therapeutic potential of neoadjuvant immunotherapy in connection with lung surgery will be of great interest for thoracic surgeons. Prospectively, the NEOMUN study has been registered on www.clinicaltrials.gov ; NCT03197467 (first post: June 23rd, 2017)." @default.
• W2943360147 created "2019-05-09" @default.
• W2943360147 creator A5013804417 @default.
• W2943360147 creator A5024703489 @default.
• W2943360147 creator A5032786481 @default.
• W2943360147 creator A5046577049 @default.
• W2943360147 creator A5053291675 @default.
• W2943360147 creator A5055278162 @default.
• W2943360147 creator A5058552522 @default.
• W2943360147 creator A5076234765 @default.
• W2943360147 date "2019-05-02" @default.
• W2943360147 modified "2023-10-17" @default.
• W2943360147 title "Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial" @default.
• W2943360147 cites W1874647622 @default.
• W2943360147 cites W1964932776 @default.
• W2943360147 cites W1966582740 @default.
• W2943360147 cites W1981976406 @default.
• W2943360147 cites W2000988149 @default.
• W2943360147 cites W2010263122 @default.
• W2943360147 cites W2010596067 @default.
• W2943360147 cites W2019607817 @default.
• W2943360147 cites W2041752578 @default.
• W2943360147 cites W2042032801 @default.
• W2943360147 cites W2071411598 @default.
• W2943360147 cites W2088720324 @default.
• W2943360147 cites W2104347254 @default.
• W2943360147 cites W2104543228 @default.
• W2943360147 cites W2109117547 @default.
• W2943360147 cites W2117115065 @default.
• W2943360147 cites W2127596453 @default.
• W2943360147 cites W2135631135 @default.
• W2943360147 cites W2146272590 @default.
• W2943360147 cites W2147592245 @default.
• W2943360147 cites W2166419674 @default.
• W2943360147 cites W2168083201 @default.
• W2943360147 cites W2181211402 @default.
• W2943360147 cites W2198093519 @default.
• W2943360147 cites W2228221433 @default.
• W2943360147 cites W2251438188 @default.
• W2943360147 cites W2327521647 @default.
• W2943360147 cites W2414258135 @default.
• W2943360147 cites W2521503673 @default.
• W2943360147 cites W2527228120 @default.
• W2943360147 cites W2527905628 @default.
• W2943360147 cites W2560367415 @default.
• W2943360147 cites W2572174216 @default.
• W2943360147 cites W2592144107 @default.
• W2943360147 cites W2792575938 @default.
• W2943360147 cites W2798160602 @default.
• W2943360147 cites W2915478882 @default.
• W2943360147 cites W93292047 @default.
• W2943360147 doi "https://doi.org/10.1186/s12885-019-5624-2" @default.
• W2943360147 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6498462" @default.
• W2943360147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31046714" @default.
• W2943360147 hasPublicationYear "2019" @default.
• W2943360147 type Work @default.
• W2943360147 sameAs 2943360147 @default.
• W2943360147 citedByCount "55" @default.
• W2943360147 countsByYear W29433601472019 @default.
• W2943360147 countsByYear W29433601472020 @default.
• W2943360147 countsByYear W29433601472021 @default.
• W2943360147 countsByYear W29433601472022 @default.
• W2943360147 countsByYear W29433601472023 @default.
• W2943360147 crossrefType "journal-article" @default.
• W2943360147 hasAuthorship W2943360147A5013804417 @default.
• W2943360147 hasAuthorship W2943360147A5024703489 @default.
• W2943360147 hasAuthorship W2943360147A5032786481 @default.
• W2943360147 hasAuthorship W2943360147A5046577049 @default.
• W2943360147 hasAuthorship W2943360147A5053291675 @default.
• W2943360147 hasAuthorship W2943360147A5055278162 @default.
• W2943360147 hasAuthorship W2943360147A5058552522 @default.
• W2943360147 hasAuthorship W2943360147A5076234765 @default.
• W2943360147 hasBestOaLocation W29433601471 @default.
• W2943360147 hasConcept C121608353 @default.
• W2943360147 hasConcept C126322002 @default.
• W2943360147 hasConcept C143998085 @default.
• W2943360147 hasConcept C2776256026 @default.
• W2943360147 hasConcept C2777701055 @default.
• W2943360147 hasConcept C2778292576 @default.
• W2943360147 hasConcept C2780057760 @default.
• W2943360147 hasConcept C2780140570 @default.
• W2943360147 hasConcept C530470458 @default.
• W2943360147 hasConcept C535046627 @default.
• W2943360147 hasConcept C71924100 @default.
• W2943360147 hasConceptScore W2943360147C121608353 @default.
• W2943360147 hasConceptScore W2943360147C126322002 @default.
• W2943360147 hasConceptScore W2943360147C143998085 @default.
• W2943360147 hasConceptScore W2943360147C2776256026 @default.
• W2943360147 hasConceptScore W2943360147C2777701055 @default.
• W2943360147 hasConceptScore W2943360147C2778292576 @default.
• W2943360147 hasConceptScore W2943360147C2780057760 @default.
• W2943360147 hasConceptScore W2943360147C2780140570 @default.
• W2943360147 hasConceptScore W2943360147C530470458 @default.
• W2943360147 hasConceptScore W2943360147C535046627 @default.
• W2943360147 hasConceptScore W2943360147C71924100 @default.
• W2943360147 hasIssue "1" @default.
• W2943360147 hasLocation W29433601471 @default.
• W2943360147 hasLocation W29433601472 @default.
• W2943360147 hasLocation W29433601473 @default.
• W2943360147 hasLocation W29433601474 @default.

• next